Condition Directory

Lung Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Lung Cancer. Browse Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 13, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

5928

Shown on this page

Current sort

How Lung Cancer studies are organized in the registry

The registry splits lung cancer records between non-small cell (NSCLC) and small cell (SCLC) disease, and a large share of NSCLC studies are organized around a biomarker rather than the diagnosis alone. If a mutation or marker drives your search, query it directly — it typically appears verbatim in titles. A dedicated non-small cell lung cancer page is also available in this directory.

Terms that often appear in related listings

NSCLC small cell lung cancer EGFR ALK KRAS

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 865–876 of 5,928 matching trials for Lung Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sotorasib, Trastuzumab Deruxtecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Sacramento, California • Tampa, Florida • Wesley Chapel, Florida + 4 more

Conditions: Non-small Cell Lung Cancer
Interventions: MGY825; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: Boston, Massachusetts • St Louis, Missouri • New York, New York + 1 more

Conditions: Smoking
Interventions: Kava, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 99 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Non-Small Cell Lung Cancer
Interventions: Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 12
States / cities: Sacramento, California • Denver, Colorado • Fort Myers, Florida + 9 more

Conditions: Extensive Stage Small Cell Lung Cancer
Interventions: Cisplatin, Carboplatin, Etoposide, Durvalumab, Ceralasertib; Drug
Lead sponsor: Muhammad Furqan; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Cervix, Non Squamous Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Esophagus, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma
Interventions: IDP-001; Drug
Lead sponsor: InduPro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Sarasota, Florida • Indianapolis, Indiana + 3 more

Conditions: Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IIIC Lung Cancer AJCC v8
Interventions: Carboplatin, Durvalumab, Gemcitabine, Local Consolidation Therapy, Nab-paclitaxel, Paclitaxel, Pemetrexed, Quality-of-Life Assessment, Questionnaire Administration; Drug · Biological · Procedure + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C, Metastatic Lung Cancer, Advanced Lung Carcinoma
Interventions: BBO-8520, Pembrolizumab, BBO-10203; Drug
Lead sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics); Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 23
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 19 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Osimertinib, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 23
States / cities: Bellflower, California • Fullerton, California • La Jolla, California + 19 more

Conditions: Advanced Cancer
Interventions: FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: RAPT Therapeutics, Inc., a member of the GSK plc group of companies; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 19
States / cities: Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: STX-241; Drug
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: Nashville, Tennessee • Houston, Texas

Conditions: Advanced Solid Tumors, Merkel Cell Carcinoma
Interventions: FF-10850 Topotecan Liposome Injection; Drug
Lead sponsor: Fujifilm Pharmaceuticals U.S.A., Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 7
States / cities: Scottsdale, Arizona • Denver, Colorado • Boston, Massachusetts + 4 more

About this Lung Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lung Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Lung Cancer clinical trials

How Lung Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

A Study of IDP-001 in Advanced or Metastatic Solid Tumors

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma

About this Lung Cancer clinical trials directory page